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DNA vaccines are a promising method of immunization against biothreats and emerging 
infections because they are relatively easy to design, manufacture, store and distribute. However, 
immunization with DNA vaccines using  conventional delivery methods often fails to induce 
consistent, robust immune responses, especially in species larger than the mouse. Intramuscular 
(i.m.) delivery of a plasmid encoding anthrax toxin protective antigen (PA) using electroporation 
(EP),  a  potent  DNA  delivery  method,  rapidly  induced  anti-PA  IgG  and  toxin  neutralizing 
antibodies within two weeks following a single immunization in multiple experimental species. 
The  delivery  procedure  is  particularly  dose  efficient  and  thus  favorable  for  achieving  target 
levels of response following vaccine administration in humans. These results suggest that EP 
may be a valuable platform technology for the delivery of DNA vaccines against anthrax and 
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1.  Introduction 
The  development  of  medical  countermeasures  for  biothreats  and  emerging  infections  has 
become a public health priority [1]. This will undoubtedly include the development of relevant 
vaccines [2]. Such vaccines should provide rapid induction of protective immune response with a 
minimal  number  of  immunizations.  They  should  also  be  compatible  with  multi-antigen 
strategies, straightforward to design, manufacture and deploy, stable upon storage, based on a 
non-immunogenic  vector,  and  safe  for  all  subjects  and  the  environment  [2].  Plasmid  DNA 
vaccines  appear  to  be  a  promising  platform  for  such  applications  because  they  are 
straightforward to design and manufacture, and exhibit a good stability profile, thereby allowing 
rapid deployment in response to novel biothreats. Since they are not based on an immunogenic 
vector, there is no concern of reduction of vaccine potency upon re-administration. Finally, DNA 
immunization is a favorable platform for the development of vaccines against a wide variety of 
targets because DNA vaccines can induce both humoral and cellular immune responses, and are 
conducive to multivalent / multi-agent strategies. Despite all of these promising characteristics, 
clinical  development  of  novel  DNA  vaccines  has  been  hampered  by  the  inability  to  induce 
consistent, high-level immune responses in humans [3].  Since a necessary condition for DNA 
immunization is the intracellular delivery of the DNA plasmid to the target cells, the inefficient 
uptake associated with conventional injection is considered a key limitation [4]. Therefore, it is 
thought  that  methods  for  enhancing  intracellular  delivery  of  DNA  vaccines  could  improve 
immunogenicity and enable the technology for clinical use [4]. In that regard, electroporation 
(EP) appears promising, because it is a potent in vivo method for intracellular gene delivery [5] 
as well as a very effective means for DNA vaccination [6-9]. Electroporation-based DNA vaccine for anthrax – Luxembourg et al. – Page 4 
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Using anthrax protective antigen (PA) as a model antigen, we have investigated the potential 
of  EP  based  DNA  immunization  for  biodefense.  PA  is  the  cell-binding  component  of  the 
Bacillus anthracis toxin, which oligomerizes to form heptamer rings at the surface of target cells 
and allows intracellular entry of the enzymatic components lethal factor (LF) and edema factor 
(EF),  thereby  causing  intoxication  [10].  PA  was  selected  for  these  studies  because  the 
development of an effective humoral immune response directed against PA can confer protection 
against anthrax [11-15], and because PA is the major protective immunogen in AVA [16, 17], an 
anthrax vaccine currently licensed in the United States. In these initial studies, we have assessed 
the characteristics of immune responses induced by a DNA vaccine candidate encoding anthrax 
PA delivered by EP in a variety of experimental species. 
 
 
2.  Materials and methods 
2.1 Animals 
Female Swiss-Webster ND4 mice (8-12 weeks) and Sprague-Dawley rats (200-250 g) were 
obtained  from  Harlan  Sprague-Dawley  (Indianapolis,  IN).  Experiments  were  approved  by 
Ichor’s Institutional Animal Care and Use Committee (IACUC) and were conducted under the 
guidelines  set  forth  by  the  National  Institutes  of  Health  in  the  Guide  for  Care  and  Use  of 
Laboratory  Animals.  Female  New  Zealand  White  rabbits  (2.5-3.0  kg)  were  housed  at  LAB 
International (San Diego, CA). Experiments were approved by LAB International’s IACUC and 
were conducted under the regulations set forth by the USDA.  
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2.2 Plasmids 
The plasmid used for vaccination, called pIMS-120, was constructed at Ichor. The nucleotide 
sequence  encoding  the  mature  83kDa  full  length  PA  protein  (without  the  29  aminoacid 
prokaryotic  secretory  signal  sequence)  (GenBank  accession  number  AF306782)  was  codon 
optimized by GeneArt (Regensburg, Germany). A construct consisting of the codon optimized 
PA gene fused with a nucleotide sequence encoding the TPA leader peptide was produced and 
cloned into the mammalian expression vector pVAX1 (Invitrogen, Carlsbad, CA). The plasmid 
was transferred into TOP10 chemically competent E.Coli (Invitrogen, Carlsbad, CA) and grown 
on  kanamycin  selective  antibiotic  plates.  Plasmid  batches  were  prepared  using  the  Qiagen 
Endofree Plasmid Giga kit (Qiagen, Valencia, CA) according to manufacturer’s instructions and 
dissolved in 1X calcium and magnesium free PBS (Mediatech Inc., Herndon, VA).  
 
2.3 Immunization procedure 
Mice and rats were anesthetized with isoflurane gas anesthesia. Rabbits were anesthetized 
either by injection of a ketamine/xylazine cocktail or with isoflurane gas anesthesia. Then, fur 
was removed over the treatment site and aseptically swabbed. Vaccine delivery was performed 
by an i.m. administration of plasmid DNA using Ichor’s TriGridÔ EP technology as previously 
reported [7]. The intraelectrode spacing of the TriGrid electrode array used in mice, rats, and 
rabbits was 2.5 mm, 3.0mm, and 6.0mm respectively. 
Mice and rats were injected into one tibialis anterior (TA) muscle. Mice were injected with 
20 ml and rats were injected with 10 ml using a 3/10cc U-100 Insulin syringe (Becton-Dickinson, 
Franklin Lakes, NJ). Unless otherwise indicated, rabbits were injected with 0.4ml into the vastus 
lateralis of one quadriceps muscle using a 1cc syringe (Becton-Dickinson) with a 23  gauge Electroporation-based DNA vaccine for anthrax – Luxembourg et al. – Page 6 
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needle. DNA dose was as indicated in the figures. Injection of DNA was immediately followed 
by electrical stimulation at an amplitude of 250 volts/centimeter of electrode spacing. The total 
duration of electrical stimulation was 40mS, applied over a 400mS interval (a 10% duty cycle). 
After completion of pulsing, the integrated TriGrid administration device was removed and the 
animal was transferred to warm recovery. Controls were treated by injecting conventional i.m. 
injection of the DNA vaccine or by EP based delivery of the vector backbone without gene insert 
(‘empty vector’). 
 
2.4 Assessment of anti-PA antibody response 
At various times following immunization, blood was collected by retro-orbital bleed in mice, 
saphenous bleed in rats or central auricular artery bleed in rabbits. Serum was recovered by 
centrifugation. Anti-PA  IgG responses were measured by  ELISA.  Briefly, serial dilutions of 
serum  samples  were  added  to  96  well  plates  coated  with  100ng/well  recombinant  PA. 
Recombinant PA was obtained from List Biological Laboratories (Campbell, CA). Biotinylated 
anti-mouse IgG (KPL, Inc., Gaithersburg, MD), anti-mouse IgG1, anti-mouse IgG2a, anti-mouse 
IgG2b, anti-mouse IgG3 (Southern Biotechnology Associates, Birmingham, AL), anti-rat IgG or 
anti-rabbit  IgG  (KPL),  as  well  as  streptavidin-horseradish  peroxidase  conjugate  (Zymed 
Laboratories, Inc., South San Francisco, CA) and SureBlue TMB microwell peroxidase substrate 
(KPL)  were  used  for  detection.  OD  reading  at  450nm  was  performed  using  a  Model  550 
microplate reader (BioRad, Hercules, CA). Antibody titer was calculated as the reciprocal of the 
sample dilution yielding an OD450 of 0.600. Total serum IgG concentration was assessed on 
some samples using an ELISA kit from Bethyl (Montgomery, TX). On selected time points, anti-Electroporation-based DNA vaccine for anthrax – Luxembourg et al. – Page 7 
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PA  antibody  titers  in  rabbits  were  also  assessed  by  ELISA  as  ￿g  anti-PA  IgG  per  ml  as 
previously described [15]. 
 
2.5 Neutralizing antibody assay 
Neutralizing  antibody  titers  were  assessed  as  previously  described  [18].  Briefly,  purified 
anthrax toxin subunits PA and LF were incubated for an hour together with various dilutions of 
serum  from  immunized  animals.  Recombinant  LF  was  obtained  from  List  Biological 
Laboratories. The mixture was then added in triplicate to J774A.1 cells (American Type Culture 
Collection, Manassas, VA) and incubated for three hours at 37
oC. Under the conditions used 
(30,000 cells per well, 20ng PA and 8ng LF per well, 96 well flat bottom plate, 100 ml final 
volume), the toxin kills virtually all J774A.1 cells. Neutralizing antibodies protect J774A.1 cells 
from  being  killed  by  the  toxin.  Cell  viability  was  measured  using  the  MTT  (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay kit (Promega, Madison, WI). Cells 
that survive exposure to the toxin are able to reduce MTT to an insoluble purple pigment. After 
incubation for two hours at 37
oC in a cell culture incubator, the pigment was solubilized by the 
addition of 100￿l of solubilization buffer according to the manufacturer instructions. OD570 was 
assessed  using  the  BioRad  Model  550  Microplate  reader.  The  OD  reading  provides  a 
proportional measure of cell viability. Antibody titer was calculated  as the reciprocal of the 
sample  dilution  yielding  an  OD570  equal  to  twice  the  background.  On  selected  time  points, 
neutralizing antibody titers in rabbits were also assessed as ED50 as previously described [15]. 
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2.6 Determination of antibody avidity 
The  avidity  of  anti-PA  antibodies  in  serum  was  estimated  using  the  thiocyanate  elution 
method  as  previously  described  [19,  20].  The  avidity  index  is  defined  as  the  molarity  of 
thiocyanate required to elute 50% of antibody under conditions of antigen excess. It is measured 
as the molarity of thiocyanate required to decrease by 50% the absorbance reading as compared 
to reading in samples in the absence of thiocyanate, assuming that the absorbance reading in the 




3.1 Enhancement of magnitude and kinetics of antibody responses in multiple species 
Swiss-Webster mice were immunized with EP or by conventional i.m. injection of 10￿g of 
the pIMS-120 plasmid in a volume of 20￿l. Blood was collected at various times following 
immunization for determination of anti-PA antibody titers in serum. As shown in Figure 1, both 
anti-PA  IgG  (Fig.  1A)  and  toxin  neutralizing  antibodies  (Fig.  1B)  were  induced  within  two 
weeks  following  a  single  immunization  with  EP  and  remained  elevated  for  the  six  months 
duration of the study in the absence of any boost immunizations. Anti-PA IgG were also induced 
in  mice  immunized  with  conventional  i.m.  injection;  however,  the  titers  were  lower,  by 
approximately one order of magnitude and response peaked later, at approximately six weeks. 
Importantly, in marked contrast to animals immunized using EP, neutralizing antibodies were 
undetectable in animals immunized with conventional i.m. injection. As shown in Table 1, total 
levels of serum IgG were not affected by either immunization methods. This shows that the 
augmentation in antibody titers following EP based immunization was not due to a massive non-
specific increase in total serum IgG.  Electroporation-based DNA vaccine for anthrax – Luxembourg et al. – Page 9 
9 
Immune responses to the vaccine delivered by EP or conventional i.m. injection were then 
assessed in Sprague-Dawley rats using the same dose of DNA (10￿g) as that used in mice. Anti-
PA IgG (Fig. 1C) and neutralizing antibodies (Fig. 1D) were rapidly induced following a single 
injection of vaccine with EP. Antibody titers remained high over the five month duration of the 
experiment.  In  contrast,  animals  immunized  with  conventional  i.m.  injection  exhibited 
inconsistent anti-PA IgG responses approximately two orders of magnitude lower than with EP. 
Consistent with the results in mice, conventional i.m. immunization did not induce detectable 
neutralizing antibodies.  
A third immunogenicity study was conducted in New Zealand White rabbits. Animals were 
immunized with 300￿g of DNA using EP or conventional i.m. injection. Consistent with the 
findings in mice and rats, EP was associated with the rapid induction of anti-PA IgG (Fig. 1E) 
and neutralizing antibodies (Fig. 1F) in all subjects following a single immunization. Antibody 
titers remained elevated for the seven month duration of the experiment. In contrast, anti-PA IgG 
titers in animals immunized with conventional i.m. injection were lower (by more than one order 
of magnitude) than with EP. No neutralizing antibodies could be detected in these animals. 
Differences were noted in the kinetics of the immune response between the three animal 
models, most notably in the toxin neutralizing antibody titers.  Additionally, the variation of the 
ELISA titers between individual animals (standard deviation) was greater at all time points in 
animals in which EP was not used.  
 
3.2 Dose efficiency 
The studies described above indicate that EP is an appropriate delivery method to enhance 
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characteristics were maintained over a broad range of vaccine doses. As shown in Figure 2, when 
the DNA was delivered by EP, a five fold dose reduction in DNA dose (from 10￿g to 2￿g) did 
not result in decreased magnitude of anti-PA IgG and neutralizing antibody responses in mice, 
remaining significantly higher than the response to 10￿g of DNA administered with conventional 
i.m. injection. At a dose of 0.4￿g of DNA administered with EP, the magnitude of the response 
trended lower. Although the geometric mean titer (GMT) was still slightly higher than with 10￿g 
of  DNA  administered  with  conventional  i.m.  injection,  the  difference  was  not  statistically 
significant. Administration of empty vector with EP did not induce an anti-PA IgG response. 
Overall, these findings suggest that EP mediated delivery enhances the potency of the PA DNA 
vaccine by between one and two orders of magnitude as compared to conventional i.m. injection. 
In order to assess the dose response of EP mediated DNA immunization in a species of larger 
body mass, rabbits were immunized at vaccine doses of 50, 150 and 500￿g. Total DNA amount 
was kept equal to 500￿g by adding the necessary amount of empty vector (pVAX1). Anti-PA 
IgG and neutralizing antibodies were assessed for 28 weeks following a single immunization 
with EP. As shown in Figure 3, delivery with EP enabled high magnitude anti-PA  IgG and 
neutralizing antibody responses to be rapidly and consistently induced in all subjects, even when 
as little as 50￿g of PA encoding DNA was administered. 
 
3.3 Further comparison of immune responses induced by EP or conventional injection 
To evaluate the induction of immunological memory and further assess the immunogenicity 
of the PA DNA vaccine delivered, a boost immunization was administered 36 weeks after the 
initial immunization to the mice described in section 3.1 and shown in Fig. 1 (A, B). As shown in 
Figure 4, anti-PA IgG titers were increased in all animals after the second immunization with Electroporation-based DNA vaccine for anthrax – Luxembourg et al. – Page 11 
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either delivery method, indicating that the vaccine induced long-term immune memory. After the 
second  immunization,  titers  in  animals  immunized  by  conventional  i.m.  injection  were 
comparable to titers measured following a single EP mediated administration. Interestingly, in 
contrast  to  the  animals  immunized  with  EP  (where  anti-PA  IgG  titers  of  this  magnitude 
correlated  with  induction  of  neutralizing  titers  in  all  subjects),  neutralizing  antibodies  were 
detectable only in some of the animals immunized by conventional i.m. injection. This remained 
the case in subsequent bleeds (data not shown). These results indicate that the magnitude of anti-
PA IgG response is not the sole determinant of induction of neutralizing antibodies.  
In  an  attempt  to  identify  other  factors  that  could  also  contribute  to  the  induction  of 
neutralizing antibodies by EP, we assessed the relative avidities of anti-PA antibody induced 
after a single immunization by EP and conventional i.m. injection, and we also measured the IgG 
subclasses  induced  by  each  immunization  method.  The  results  of  representative  avidity 
measurements are shown in Table 2. As indicated in the table, there was no significant difference 
in  antiserum  avidity  for  PA  between  the  cohorts  immunized  with  EP  and  conventional  i.m. 
injection. Examination of IgG subclasses (Fig. 5A) induced by immunization revealed that the 
subclasses induced by conventional i.m. injection of the vaccine were mainly IgG1 and IgG2a. EP 
based  vaccination  markedly  enhanced  both  IgG1  and  IgG2a  with  a  statistically  significant 
induction of the GMT of 11.3 fold for IgG1 and a slightly lower induction of 6.7 fold for IgG2a. 
The ratio of IgG1 titers to IgG2a titers in individual animals appeared consistent between the two 
immunization methods since we found no statistically significant difference between the two 
immunization groups (Fig. 6B). This indicated that the relative induction of the two subclasses 
was comparable between the two immunization methods. IgG2b titers were relatively modest as 
compared to IgG1 and IgG2a titers; they were found elevated in the group immunized with EP as Electroporation-based DNA vaccine for anthrax – Luxembourg et al. – Page 12 
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compared to the group immunized with conventional i.m. injection, although the induction was 
more  limited  (2.6  fold)  than  with  IgG1  or  IgG2a.  This  difference  in  IgG2b  induction  was 
statistically significant between the two immunization groups in the experiment presented in 
Fig.6,  but  not  in  a  repeat  study  (not  shown).  Anti-PA  IgG3  were  not  detectable  in  animals 
immunized by either method. Overall, there did not appear to be a notable difference in the 
composition of antigen specific IgG subclasses following immunization with EP or conventional 
i.m. injection. 
 
3.4 Potential for induction of protective immunity 
Antibody  responses  obtained  in  rabbits  following  a  single  immunization  with  EP  or 
conventional i.m. injection were re-assessed on selected time points using the same assays that 
have been used previously to assess protective antibody titers for inhalation anthrax in the rabbit 
model [15]. The results of this evaluation, including anti-PA IgG and neutralizing antibody are 
shown in Figure 6. The results are consistent with above results showing the potentiation of 
immune responses to PA using EP. Importantly, anti-PA IgG and neutralizing antibody titers 
induced using EP were comparable to titers previously reported [15] in rabbits immunized with 
rPA and found protected against inhalation anthrax. 
 
4. Discussion  
When compared to conventional i.m. injection, EP enhanced multiple aspects of immune 
responses to DNA vaccination for anthrax PA in several species. The magnitude of anti-PA IgG 
responses was increased by approximately one order of magnitude in mice and by one to two 
orders of magnitude in rats and rabbits. In addition, in all three species, EP based vaccination Electroporation-based DNA vaccine for anthrax – Luxembourg et al. – Page 13 
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exhibited  more  rapid  response  and  lower  inter-subject  variability  in  anti-PA  IgG  titers  than 
conventional i.m. injection. In all species tested, EP based immunization induced neutralizing 
antibodies in 100% of the subjects within 2-3 weeks following a single immunization. This was 
in marked contrast to conventional i.m. injection which did not induce a detectable neutralizing 
antibody response in the vast majority of animals. EP also greatly improved the dose efficiency 
of  the  PA  DNA  vaccine,  inducing  consistent,  high  magnitude  immune  responses  even  at 
relatively low dose levels. Although there was some variation in the kinetics of response among 
the  three  species  tested,  it  is  notable  that  EP  mediated  delivery  of  the  vaccine  induced 
comparable levels of toxin neutralizing antibodies in mice, rats and rabbits. This represents an 
absolute comparison since the exact same assay was used with all three species. Assessment of 
quantitative  anti-PA  IgG  titers  indicated  that  peak  anti-PA  IgG  titers  in  sera  from  rabbits 
immunized  with  EP  were  greater  than  100￿g  anti-PA  IgG  per  ml  serum.  These  titers  are 
comparable  to  titers  previously  measured  using  the  same  method  at  the  peak  of  antibody 
responses in rabbits immunized with recombinant PA (rPA) adsorbed to aluminum hydroxide 
and  resistant  to  challenge  with  live  anthrax  spores  (Figure  3  in  ref.  [15]).  Anthrax  toxin 
neutralizing  antibodies  were  also  induced  in  rabbits  immunized  with  EP  with  ED50  values 
comparable to those previously found to be protective in rabbits immunized with rPA (Figure 4 
in  ref.  [15]).  These  results  are  significant  since  antibody  responses  to  PA  are  considered  a 
correlate for protection against inhalation anthrax [12, 13, 15]. 
We cannot completely explain the difference between the two immunization methods for 
induction of neutralizing antibodies. It is likely that several mechanisms contribute to the ability 
of EP to enable the rapid induction of neutralizing antibodies. As discussed above, even though 
the magnitude of anti-PA IgG response is an important determinant of the magnitude of the Electroporation-based DNA vaccine for anthrax – Luxembourg et al. – Page 14 
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neutralizing antibody response, there is not a perfect correlation between the two responses. We 
found no difference between the two immunization methods with regards to antibody avidities 
and  IgG  subclass  distribution,  two  elements  that  we  thought  could  have  played  a  role  in 
neutralizing antibody induction. One could speculate about other factors may contribute to the 
difference.  For  instance,  recent  reports  have  shown  that  EP  can  induce  reactivity  against  a 
broader  range  of  epitopes  than  conventional  vaccine  administration.  Thus  far,  this  has  been 
demonstrated only with T cell epitopes [7-9]. If this is also the case for B cell epitopes, this could 
include epitopes that are critical for neutralizing activity.  
Regardless  of  the  method  of  administration,  our  anthrax  PA  DNA  vaccine  candidate 
preferentially induced anti-PA IgG of the IgG1 subclass over the IgG2a subclass, which indicates 
a Th2 skew of the response. Although DNA vaccines are generally considered strong inducers of 
Th1 responses, previous observations suggest that this may not be the case for all antigens [21]. 
In fact, preferential induction of the IgG1 over the IgG2a subclass has been noted previously with 
vaccines for anthrax PA, including protein [22] and other DNA [23] based vaccines. In that latter 
study, direct measurement of T cell cytokine indicated that despite the stronger induction of IgG1 
than  IgG2a,  both  Th1  and  Th2  cytokines  were  induced  to  a  comparable  extent  [23],  which 
suggests  that  DNA  vaccination  elicited  a  mixed  Th1  /  Th2  response.  Overall,  this  response 
profile may be favorable to induce protection against anthrax. Since the majority of anti-PA 
monoclonal antibodies capable of toxin neutralization produced so far are of the IgG1 subclass 
[24], vaccines inducing this subclass may be favorable for toxin neutralization. On another hand, 
preserving a Th1 component in the response may help in other aspects of protective immunity 
[25]. Electroporation-based DNA vaccine for anthrax – Luxembourg et al. – Page 15 
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The strong enhancement of immune responses by EP provides encouragement that EP-based 
immunization may be useful for the development of DNA vaccines. Several characteristics of EP 
based DNA immunization observed in the present study are of interest for the development of 
vaccines  for  biodefense.  First,  the  dose  efficiency  associated  with  EP  is  conducive  to  the 
inclusion of more than one plasmid, and thus to the development of multivalent / multi-agent 
vaccines.  Second,  EP  is  associated  with  a  fast  onset  of  immune  responses  with  few 
immunizations, which is favorable for applications where a rapid response is required. Recent 
epidemiological  studies  on  the  2001-2002  anthrax  attack  in  the  US  [26,  27]  showed  that 
antibiotic  treatment  provided  sub-optimal  protection  against  the  disease  and  indicated  that  a 
multi-modality treatment combining antibiotics with another intervention capable of providing 
rapid  protection  (within  less  than  4  weeks)  could  significantly  improve  treatment  outcome 
following anthrax exposure. These studies indicate that the earlier the onset of protection, the 
more  beneficial  the  additional  treatment.  From  a  practical  and  logistical  perspective,  the 
intervention would ideally require a minimal number of administrations to maintain protection. 
The results we have obtained using anthrax PA as a model antigen are potentially relevant to 
other biothreats for which the major component of protection is the generation of an antibody 
response.  In  particular,  neutralizing  antibodies  against  antigens  that  play  a  key  role  in 
pathogenesis, such as viral envelope glycoproteins and bacterial toxins, are considered correlates 
for immunity for a number of agents. Based on studies by Ichor (unpublished) and others [28], 
EP appears to favor the induction of neutralizing antibodies with other antigens as well. Of note, 
DNA vaccines are known to induce strong T cell responses. T cell responses increasingly appear 
as  an  important  protective  mechanism,  even  with  agents  like  anthrax  for  which  antibody 
responses  are  the  only  identified  correlate  for  immunity  [25].  Therefore,  EP  based  DNA Electroporation-based DNA vaccine for anthrax – Luxembourg et al. – Page 16 
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vaccination may offer the additional benefit of inducing strong cellular immune responses [7-9, 
29, 30]. 
Based on its ability to promote the rapid induction of broad immune responses with relatively 
few immunizations, this platform technology may facilitate the development of vaccines against 
agents for which traditional vaccination methods are either inefficient or ineffectual. Preparations 
are now underway for further development of this anthrax vaccine, including efficacy and safety 
studies designed to support human clinical studies. In addition, the promising results observed 
with anthrax DNA vaccines have led to the initiation of pre-clinical investigations of EP based 




We thank Dr. Stephen Leppla (NIAID, NIH) for reagents and advice, and Dr. Edwin Ades 
(CDC, Atlanta, GA) for helpful discussions and advice. We also thank Katie Bernard, Jessica 
Hankins,  Michael  Lao,  Elizabeth  Lung,  Pamela  Rahn  and  Rafael  Villanueva  for  technical 
assistance,  and  Lacey  Tichenor  for  outstanding  administrative  assistance.  This  work  was 




1.  Parker G. Office of the Assistant Secretary for Preparedness and Response; HHS Public 
Health  Emergency  Medical  Countermeasures  Enterprise  Strategy  for  Chemical, 
Biological, Radiological and Nuclear Threats. Fed Register 2007; 72(53):13109-14. Electroporation-based DNA vaccine for anthrax – Luxembourg et al. – Page 17 
17 
2.  Galloway DR, Baillie L. DNA vaccines against anthrax. Expert Opin Biol Ther 2004; 
4(10):1661-7. 
3.  van Drunen Littel-van den Hurk S, Loehr BI, Babiuk LA. Immunization of livestock with 
DNA vaccines: current studies and future prospects. Vaccine 2001; 19(17-19):2474-9. 
4.  Ulmer  JB,  Wahren  B,  Liu  MA.  Gene-based  vaccines:  recent  technical  and  clinical 
advances. Trends Mol Med 2006; 12(5):216-22. 
5.  Luo D , Saltzman WM. Synthetic DNA delivery systems. Nat Biotechnol 2000; 18(1):33-
7. 
6.  Widera G, Austin M, Rabussay D, Goldbeck C, Barnett SW, Chen M, et al. Increased 
DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000; 
164(9):4635-40. 
7.  Luxembourg A, Hannaman D, Ellefsen B, Nakamura G, Bernard R. Enhancement of 
immune  responses  to  an  HBV  DNA  vaccine  by  electroporation.  Vaccine  2006; 
24(21):4490-3. 
8.  Capone  S,  Zampaglione  I,  Vitelli  A,  Pezzanera  M,  Kierstead  L,  Burns  J,  et  al. 
Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus 
DNA vaccine in nonhuman primates. J Immunol 2006; 177(10):7462-71. 
9.  Luckay A, Sidhu MK, Kjeken R, Megati S, Chong SY, Roopchand V, et al. Effect of 
plasmid  DNA  vaccine  design  and  in  vivo  electroporation  on  the  resulting  vaccine-
specific immune responses in rhesus macaques. J Virol 2007; 81(10):5257-69. 
10.  Moayeri M, Leppla SH. The roles of anthrax toxin in pathogenesis.  Curr Opin Microbiol 
2004; 7(1):19-24. Electroporation-based DNA vaccine for anthrax – Luxembourg et al. – Page 18 
18 
11.  Turnbull PC, Leppla SH, Broster MG, Quinn CP, Melling J. Antibodies to anthrax toxin 
in humans and guinea pigs and their relevance to protective immunity. Med Microbiol 
Immunol (Berl) 1988; 177(5):293-303. 
12.  Pitt  ML,  Little  S,  Ivins  BE,  Fellows  P,  Boles  J,  Barth  J,  et  al.  In  vitro  correlate  of 
immunity in an animal model of inhalational anthrax. J Appl Microbiol 1999; 87(2):304. 
13.  Pitt ML, Little SF, Ivins BE, Fellows P, Barth J, Hewetson J, et al. In vitro correlate of 
immunity in a rabbit model of inhalational anthrax. Vaccine 2001; 19(32):4768-73. 
14.  Fellows PF, Linscott MK, Ivins BE, Pitt ML, Rossi CA, Gibbs PH, et al. Efficacy of a 
human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by 
Bacillus anthracis isolates of diverse geographical origin. Vaccine 2001; 19(23-24):3241-
7. 
15.  Little  SF,  Ivins  BE,  Fellows  PF,  Pitt    MLM,  Norris  SLW,  Andrews  GP.  Defining  a 
serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 
2004; 22:422-30. 
16.  Ivins  BE,  Welkos  SL,  Little  SF,  Crumrine  MH,  Nelson  GO.  Immunization  against 
anthrax  with  Bacillus  anthracis  protective  antigen  combined  with  adjuvants.  Infect 
Immun 1992; 60(2):662-8. 
17.  Little SF. Anthrax vaccines: a development update. BioDrugs 2005; 19(4):233-45. 
18.  Price BM, Liner AL, Park S, Leppla SH, Mateczun A, Galloway DR. Protection against 
anthrax  lethal  toxin  challenge  by  genetic  immunization  with  a  plasmid  encoding  the 
lethal factor protein. Infect Immun 2001; 69(7):4509-15. 
19.  Pullen GR, Fitzgerald MG, Hosking CS. Antibody avidity determination by ELISA using 
thiocyanate elution. J Immunol Methods 1986; 86(1):83-7. Electroporation-based DNA vaccine for anthrax – Luxembourg et al. – Page 19 
19 
20.  Ferreira MU, Katzin AM. The assessment of antibody affinity distribution by thiocyanate 
elution: a simple dose-response approach. J Immunol Methods 1995; 187(2):297-305. 
21.  Kim SA, Liang CM, Cheng IC, Cheng YC, Chiao MT, Tseng CJ, et al. DNA vaccination 
against foot-and-mouth disease via electroporation: study of molecular approaches for 
enhancing VP1 antigenicity. J Gene Med 2006; 8(9):1182-91. 
22.  Williamson  ED,  Beedham  RJ,  Bennett  AM,  Perkins  SD,  Miller  J,  Baillie  LW. 
Presentation  of  protective  antigen  to  the  mouse  immune  system:  immune  sequelae.  J 
Appl Microbiol 1999; 87(2):315-7. 
23.  Gu ML, Leppla SH, Klinman DM. Protection against anthrax toxin by vaccination with a 
DNA plasmid encoding anthrax protective antigen. Vaccine 1999; 17(4):340-4. 
24.  Little SF, Novak JM, Lowe JR, Leppla SH, Singh Y, Klimpel KR, et al. Characterization 
of  lethal  factor  binding  and  cell  receptor  binding  domains  of  protective  antigen  of 
Bacillus anthracis using monoclonal antibodies. Microbiology 1996; 142(Pt. 3):707-15. 
25.  Glomski  IJ,  Corre  JP,  Mock  M,  Goossens  PL.  IFN-gamma-producing  CD4  T 
lymphocytes  mediate  spore-induced  immunity  to  capsulated  Bacillus  anthracis.  J 
Immunol 2007; 178(5):2646-50. 
26.  Brookmeyer R, Johnson E, Bollinger R. Public health vaccination policies for containing 
an anthrax outbreak. Nature 2004; 432(7019):901-4. 
27.  Fowler RA, Sanders GD, Bravata DM, Nouri B, Gastwirth JM, Peterson D, et al. Cost-
effectiveness  of  defending  against  bioterrorism:  a  comparison  of  vaccination  and 
antibiotic prophylaxis against anthrax. Ann Intern Med 2005; 142(8):601-10. Electroporation-based DNA vaccine for anthrax – Luxembourg et al. – Page 20 
20 
28.  Law  M,  Cardoso  RM,  Wilson  IA,  Burton  DR.  Antigenic  and  immunogenic  study  of 
membrane-proximal  external  region-grafted  gp120  antigens  by  a  DNA  prime-protein 
boost immunization strategy. J Virol 2007; 81(8):4272-85. 
29.  Zucchelli S, Capone S, Fattori E, Folgori A, Di Marco A, Casimiro D, et al. Enhancing 
B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular 
electrical gene transfer. J Virol 2000; 74(24):11598-607. 
30.  Otten G, Schaefer M, Doe B, Liu H, Srivastava I, zur Megede J, et al. Enhancement of 
DNA  vaccine  potency  in  rhesus  macaques  by  electroporation.  Vaccine  2004; 
22(19):2489-93. Electroporation-based DNA vaccine for anthrax – Luxembourg et al. – Page 21 
21 
Table 1: Total serum IgG levels in mice immunized with EP or conventional i.m. injection  








Total serum IgG (mg/ml)* 
± 1 SD  0.88 ± 0.10  1.15 ± 0.29  0.75 ± 0.10  0.89 ± 0.24  0.95 ± 0.12 
*Assessment at day 14 following a single immunization 
 
 
Table 2: Relative anti-PA IgG avidities in serum of mice immunized with EP or conventional 
i.m. injection  
Immunization 
method 
Avidity index measured in individual 
animals (expressed in mM NH4SCN)*  
Average 
(± 1 SD)  p value ** 
EP  746, 797, 847, 932, 983, 1254  927 (±182)  
Conventional i.m. 
injection  424, 457, 525, 729, 814, 1254  701 (±312) 
p>0.05 
*Assessment at day 42 following a single immunization with 10￿g of DNA 




Figure 1: Induction of anti-PA IgG and toxin neutralizing antibody responses following a single 
EP based immunization in mice, rats and rabbits 
Swiss-Webster mice (A, B) and Sprague-Dawley rats (C, D) were immunized at day 0 with 10 
mg pIMS-120 plasmid in one TA muscle. New Zealand White rabbits (E, F) were immunized at 
day 0 with 300 mg pIMS-120 plasmid in one quadriceps. Vaccine was administered with EP 
(filled  diamonds,  solid  lines)  or  conventional  i.m.  injection  (empty  diamonds,  broken  lines). 
Anti-PA Ig titers (A, C, E) and toxin neutralizing antibodies (B, D, F) were assessed in serum at 
various times. Error bars represent one standard deviation. 
 
Figure 2: Dosing study in mice 
 Swiss-Webster mice were immunized at day 0 by injecting in one TA muscle 10 mg (filled 
diamonds), 2 mg (filled squares), or 0.4 mg  (filled triangles) pIMS-120 with EP or 10 mg (empty 
diamonds) pIMS-120 plasmid by conventional i.m. injection. Controls received empty vector 
with  EP  (cross).  Preimmune  levels  are  indicated  by  a  circle.  Six  weeks  after  immunization, 
serum  was  collected,  and  anti-PA  Ig  titers  (A)  and  toxin  neutralizing  antibodies  (B)  were 
assessed. Horizontal bars represent the geometric mean titers. Statistical difference of each EP 
group relative to the conventional i.m. injection group are shown as * (p<0.05) and ** (p<0.01) 
using a one sided Student’s t test assuming a lognormal distribution. 
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Figure 3: Dosing study in rabbits 
New Zealand White rabbits were immunized at day 0 by injecting in one quadriceps 500mg 
pIMS-120 (diamonds), 150mg pIMS120 + 350mg pVAX.1 (squares), or 50mg pIMS-120 + 450mg 
pVAX.1 (triangles) in a volume of 500ml with EP. Anti-PA Ig titers (A) and toxin neutralizing 
antibodies (B) were assessed in serum at various time points. Error bars represent one standard 
deviation. 
 
Figure 4: Comparison of immune responses following one and two immunizations in mice 
Swiss-Webster mice were immunized at day 0 by injecting in one TA muscle 10 mg pIMS-120 
with EP (filled diamonds) or conventional i.m. injection (empty diamonds). A second identical 
immunization  was  administered  in  the  contralateral  TA  at  week  36  following  the  initial 
immunization. Anti-PA IgG (A) and neutralizing antibodies (B) were assessed at 6 weeks and 38 
weeks. Horizontal bars represent the geometric mean titers. Statistical difference of each EP 
group relative to the conventional i.m. injection group are shown as * (p<0.05) and ** (p<0.01) 
using a one sided Student’s t test assuming a lognormal distribution. 
 
Figure 5: Determination of IgG subclasses in mice 
Swiss-Webster mice were immunized at day 0 by injecting in one TA muscle 10 mg pIMS-120 
with EP (grey) or conventional i.m. injection (white). Anti-PA IgG1, IgG2a, IgG2b and IgG3 titers 
were assessed in serum at 16 weeks. (A) Geometric mean titers are shown in grey for the group 
immunized with EP and in white for the group immunized by conventional i.m. injection. Error 
bars represent one standard deviation. (B) Ratios of IgG1 titers to IgG2a titers in each individual 
animal were calculated for the EP group (black diamonds) and conventional i.m. injection group Electroporation-based DNA vaccine for anthrax – Luxembourg et al. – Page 24 
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(white  diamonds).  Statistical  difference  of  each  EP  group  relative  to  the  corresponding 
conventional i.m. injection group are shown as * (p<0.05) and ** (p<0.01) using a one sided 
Student’s t test assuming a lognormal distribution. 
 
Figure 6: Reassessment of anti-PA IgG and toxin neutralizing antibody responses following a 
single EP based immunization in rabbits using a standardized assay 
New  Zealand  White  rabbits  were  immunized  as  indicated  in  Figure  1.  Anti-PA  IgG  and 
neutralizing antibody were assessed on selected serum samples using standardized assays that 
have  been  used  to  determine  immune  correlates  for  protection  against  inhalation  anthrax  in 
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